Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | PARP1 | P09874 | 11/20 | 0.58 |
| ▸ | AR | P10275 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573126 | 0.83 | PARP1 (0.62) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL6610436 | 0.83 | PARP1 (0.62) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL12798188 | 0.78 | PARP1 (0.70) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL581787 | 0.78 | AR (0.70) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL26907276 | 0.78 | PARP1 (0.58) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL8270690 | 0.78 | PARP1 (0.58) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL76707 | 0.78 | PARP1 (0.62) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL905630 | 0.77 | AR (0.79) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL3386656 | 0.77 | CYP3A4 (0.80) | TSHRCYP3A4CYP2C9CYP2C19PARP1 | |
| SCHEMBL12955520 | 0.77 | CYP3A4 (0.80) | TSHRCYP3A4CYP2C9CYP2C19PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165173-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | TSHR 3461/4885CYP3A4 1659/4885CYP2C9 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.